

11th April 2012



GlaxoSmithKline

Professor David Healy
Data Based Medicine Global Limited.
2-8 Farrar Road
Bangor
Gwynedd
LL57 1LJ
United Kingdom

**GlaxoSmithKline Research
& Development Limited**
Medicines Research Centre
Gunnels Wood Road
Stevenage
Hertfordshire
SG1 2NY
Tel. +44 (0)1438 745745
www.gsk.com

Dear Professor Healy,

Thank you very much for your letter of March 16, 2012 to Sir Andrew Witty inviting GlaxoSmithKline to collaborate with you in your new website, Rxisk.org. We are pleased to hear you describe GSK as "one of the more responsible pharmaceutical companies in the field" and appreciate that recognition.

As you probably know, GSK has a commitment to transparency, including such things as the Clinical Trial Registry on our website and a commitment to publish clinical trial results. GSK takes the reporting of adverse events very seriously, and patients and health care providers regularly contact GSK to report adverse events. GSK submits such reports to regulatory bodies in accordance with its regulatory obligations.

Patient reporting sites, which take varying approaches, are certainly developing areas. GSK is following these and their progress with interest, however, and after careful review, we do not believe that Rxisk.org would be an appropriate candidate for GSK participation.

Thank you again for giving GSK the opportunity to consider your proposal.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'S Hobbiger', written in a cursive style.

Dr SF Hobbiger
EU Qualified Person for Pharmacovigilance
GlaxoSmithKline

Registered in England & Wales
No. 835139

Registered office
980 Great West Road
Brentford, Middlesex. TW8 9GS